6-Shogaol (Ginger)

ROS↑ and ER-stress apoptosis; NF-κB/EMT↓; preclinical adjunct.

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preliminary — Robust cell/animal data across tumor types; human cancer trials are limited/absent, so clinical efficacy is unproven.Dehydrated 6-gingerolGinger phenolic

Forms: Standardized ginger extract (6-shogaol-rich) · Whole ginger (variable 6-shogaol)

Educational only, not medical advice. OncoForge makes no claim that 6-Shogaol (Ginger) treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

This ginger compound pushes cancer cells into overwhelming stress: it floods them with ROS, jams their protein-folding machinery, and flips on death switches—while turning down pathways they use to invade and spread. It also hits stem-like tumor cells that seed relapse. Evidence is mostly lab/animal so far, but it’s a strong adjunct candidate in preclinical work.

Evidence at a glance

Tier 1 · labBreastColonOvarianLung

Robust in vitro/in vivo signals; human oncology efficacy unproven.

How it may work

6-Shogaol, the dehydrated form of 6-gingerol, kills cancer cells by triggering mitochondrial/ER-stress apoptosis driven by reactive oxygen species (ROS) and the PERK–eIF2α–ATF4–CHOP axis (up to DR5 activation). It suppresses NF-κB/IKK and STAT3 signaling, lowering MMP-2/MMP-9 and EMT drivers (Snail/Slug/vimentin), which reduces invasion and metastasis. It also targets cancer stem-like cells (e.g., CD44+CD24−/low/ALDH1+ spheres) and can induce paraptosis-like vacuolization. In models, 6-shogaol enhances sensitivity of drug-resistant cells (e.g., gefitinib-resistant ovarian) via ER-stress–mediated apoptosis.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

ROS↑Mito/ER ROS; context-dependent
Apoptosis↑PERK–eIF2α–ATF4–CHOP → DR5
NF-κB↓IKKβ inhibition; MMP-9↓
EMT↓Snail/Slug/Vimentin↓; invasion↓
STAT3↓

ROS ↑Apoptosis ↑NF-κB ↓EMT ↓

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Curcumin: Additive NF-κB↓ + ROS↑ can amplify apoptosis
EGCG: Convergent NF-κB/PI3K pathway dampening

Overlapping mechanisms

NF-κB: Avoid stacking too many NF-κB↓ agents without purpose.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Bleeding RiskDiarrhea RiskPregnancy Avoid

Potential interactions

anticoagulants_rxMonitorModerateTheoreticalAntiplatelet activity may increase bleeding risk.
ROS-dependent chemotherapy/radiationMonitorTheoreticalDual pro-oxidant (synergistic in tumors via ROS amplification) and antioxidant (protective in normal tissues) effects; time post-therapy peak to avoid potential blunting of ROS waves while leveraging efficacy.

Timing

With-meal: Improves GI tolerance.
AM
PM

References

Research

No published studies for 6-Shogaol (Ginger) yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of 6-Shogaol (Ginger) depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 5–10 mg (oral) divided; with food; product-dependent (from standardized extract), Human anti-cancer dosing uncertain; based on PK trial extrapolations. GI tolerance often limits higher intake. For oncology, start low and monitor..

Trials studying 6-Shogaol (Ginger)

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar